➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
Baxter
AstraZeneca
Boehringer Ingelheim
Dow

Last Updated: January 28, 2021

DrugPatentWatch Database Preview

Patent: 9,086,418

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,086,418
Title:Methods and compositions for diagnosing ankylosing spondylitis using biomarkers
Abstract: The invention provides a method for determining the efficacy of a TNF.alpha. inhibitor, such as a TNF.alpha. antibody, or an antigen-binding portion thereof, for treating ankylosing spondylitis (AS), using a collagen degradation biomarker and/or a synovitis biomarker.
Inventor(s): Maksymowych; Walter P. (Edmonton, CA), Wong; Robert L. (Basking Ridge, NJ)
Assignee: ABBVIE BIOTECHNOLOGY LTD. (Hamilton, BM)
Application Number:13/034,809
Patent Claims:see list of patent claims

Details for Patent 9,086,418

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Abbvie Inc HUMIRA adalimumab VIAL 125057 002 2002-12-31   Start Trial ABBVIE BIOTECHNOLOGY LTD. (Hamilton, BM) 2021-03-07 RX Orphan search
Abbvie Inc HUMIRA adalimumab SYRINGE 125057 001 2002-12-31   Start Trial ABBVIE BIOTECHNOLOGY LTD. (Hamilton, BM) 2021-03-07 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 9,086,418

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 2007089303   Start Trial
United States of America 2007172897   Start Trial
United States of America 2012129185   Start Trial
United States of America 7919264   Start Trial
Taiwan 200736611   Start Trial
Taiwan 201337266   Start Trial
Taiwan I424161   Start Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
Mallinckrodt
Johnson and Johnson
Boehringer Ingelheim
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.